Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1344
- Registration Number
- NCT01484262
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Flyvbjerg, Allan, DMSc
- Target Recruit Count
- 240
- Registration Number
- NCT01472640
- Locations
- 🇩🇰
Skejby University Hospital, Aarhus, Denmark
🇩🇰Steno Diabetes Center, Gentofte, Denmark
🇩🇰Herlev University Hospital, Herlev, Denmark
Identifying Potential Effects of Liraglutide on Degenerative Changes
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 34
- Registration Number
- NCT01469351
- Locations
- 🇩🇰
Aarhus University, Aarhus, Denmark
The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Annesofie Faurschou
- Target Recruit Count
- 20
- Registration Number
- NCT01460069
- Locations
- 🇩🇰
Gentofte Hospital, Hellerup, Denmark
GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2012-06-21
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 12
- Registration Number
- NCT01451905
- Locations
- 🇩🇰
Gentofte Hospital, Hellerup, Denmark
Liraglutide and Heart Failure in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- Thomas Nystrom
- Target Recruit Count
- 62
- Registration Number
- NCT01425580
- Locations
- 🇸🇪
Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden
🇸🇪Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB, Stockholm, Sweden
Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4121
- Registration Number
- NCT01403025
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Liraglutide Treatment to Patients With Severe Renal Insufficiency
- Conditions
- Interventions
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2013-10-09
- Lead Sponsor
- Bo Feldt-Rasmussen
- Target Recruit Count
- 40
- Registration Number
- NCT01394341
- Locations
- 🇩🇰
Department of Endocrinology PE, Copenhagen University Hospital, Rigshospitalet, Copenhagen Ø, Copenhagen, Denmark
🇩🇰Department of Nephrology P, Copenhagen University Hospital, Rigshospitalet, Copenhagen Ø, Copenhagen, Denmark
🇩🇰Department of Internal Medicine H, Hillerød Hospital, Hillerød, Denmark
Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT01392898
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin
- Conditions
- Interventions
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 413
- Registration Number
- NCT01388361
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.